2 results about "Macrophage migration inhibitory factor" patented technology

This invention provides a biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions, its preparation method, and its application. The biomimetic nanoparticle composite PRP hydrogel is formed by cross-linking a hydrogel matrix and composite nanoparticles dispersed therein. The core of the composite nanoparticles is albumin nanoparticles loaded with macrophage migration inhibitory factor inhibitors, and the outer shell of the composite nanoparticles is a fibroblast membrane. The preparation method includes the following steps: preparing a composite nanoparticle dispersion; mixing sodium alginate with the composite nanoparticle dispersion to prepare a sodium alginate solution; adding platelet-rich plasma and mixing evenly; adding calcium carbonate and an acidity regulator; stirring evenly and allowing to stand to form a gel, thus obtaining the biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions.

Provided herein are methods of reducing immune checkpoint therapy resistance, increasing immune checkpoint therapy sensitivity and / or increasing anti-tumor activity in subjects with cancer, methods of treating non-small cell lung cancer (NSCLC), and methods of identifying a subject as a responder to a macrophage migration inhibitory factor (MIF) targeting agent therapy. The methods include identifying alteration in the KEAP1 / NRF2 pathway and administering MIF targeting agent therapy. Illustrative immune checkpoint therapies include PD-1 inhibitors and / or PD-L1 inhibitors.